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In 1999, the US Food and Drug Administration approved the
use of rVIIa for the treatment of bleeding in patients with hemo-
philia A or B and inhibitors of factors VII and IX. Since then, rVIIa
has been increasingly used off-label to treat surgical patients with-
out hemophilia that have intractable bleeding. Koncˇar et al de-
scribe the largest case series of vascular patients treated with rVIIa.
Like numerous earlier case reports and case series, the current
article describes the use of rVIIa to decrease blood transfusion
requirements and correct coagulopathy after major operations
associated with serious nonsurgical bleeding.1,2 The current series
also highlights a significant survival advantage for patients treated
with rVIIa compared to a historical control group. Similarly, a
meta-analysis of case series analyzing the use of rVIIa in major
abdominal operations found a 73% mean reduction or cessation of
bleeding and a 53% mean probability of survival after administra-
tion of rVIIa.1
Activated factor VII (VIIa) is believed to complex with tissue
factor in the subendothelium at sites of injury, leading to the
activation of factors IX and X and the generation of thrombin.3
Because of its mechanism of action, there exists the potential for
thrombotic complications which must be balanced with rVIIa’sroup. A review of the Food & Drug Administration’s Adverse
vent Reporting System between 1999 and 2004 for thromboem-
olic adverse events (TAEs) with rVIIa, led the authors to con-
lude that there was a substantial risk of TAEs.4 The majority of
AEs occurred with the use of rVIIa for unlabeled indications, and
rterial thrombotic complications were the most common. A sub-
equent meta-analysis of case series calculated a mean probability
f 16.5% for thrombemboli associated with rVIIa use during
bdominal surgery.1 A recent meta-analysis of randomized con-
rolled trials comparing rVIIa to placebo found that TAEs oc-
urred in 8.6% of the rVIIa group compared to 6.4% in the placebo
roup.2 However, arterial TAEs occurred more frequently in the
VIIa group compared to placebo. Despite the lack of TAEs in the
urrent article, a review of the literature would suggest that an
ncreased risk of thrombotic complications is suspected that can
nly be ascertained by randomized controlled trials.
Koncˇar et al’s routine use of rVIIa for intractable bleeding in
atients treated for ruptured abdominal aortic aneurysms (RAAAs)
nd elective thoracoabdominal aortic aneurysms (TAAAs) resulted
n a significant reduction in mortality rate (13%), a significant
ecrease in transfusion requirement, and rapid correction of inter-
ational normalized ratio compared to their retrospective histori-
al control group. However, these results are not sufficient to
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limitation of their study arises from mixing historical controls
with a prospective series in that you can never eliminate possible
biases due to factors such as improvements in anesthesia or
blood banks, that may have changed over time.5 When random-
ized trials are compared to historical control testing series of the
same intervention, patient selection bias weighs the outcome of
historical control testing in favor of the new intervention.6 The
authors realize that using a heterogeneous population of pa-
tients with RAAA and elective TAAA weakens their results, as it
is likely that the cause of coagulopathy and other variables differ
between groups.
As vascular surgeons, we have all cared for patients that
developed nonsurgical, perioperative bleeding despite aggressive
replacement of coagulation products, and we wished for an addi-
tional measure to use. The authors are to be commended for their
improvement in survival of vascular patients with intractable bleed-
ing after the administration of rVIIa. However, the reader should
thoughtfully consider the limitations of this study before changinguidelines for rVIIa, verify its safety and efficacy, and define indi-
ations for its use in vascular patients.
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